MDV Medivation

SAN FRANCISCO, Dec. 5 /PRNewswire-FirstCall/ -- Medivation, Inc. (AMEX:MDV) today announced the appointment of Sue Wollowitz, Ph.D., as vice president, chemistry and manufacturing. Dr. Wollowitz, who has more than 20 years of experience in drug discovery and development, joins Medivation as a member of the senior management team. "Dr. Wollowitz is a seasoned executive with extensive experience and leadership in the biopharmaceutical industry. Her addition helps us broaden our team of highly-qualified and experienced biopharmaceutical professionals, which will be critical as we continue to advance our lead product candidate Dimebon(TM) for the treatment of Alzheimer's and Huntington's disease," said David Hung, M.D., president and chief executive officer of Medivation. For the past three years, Dr. Wollowitz has served as president of Wollowitz Associates, a consulting business that assists small and emerging pharmaceutical companies in process scale-up, outsourcing, in-licensing and regulatory approvals. Prior to that, she held various senior positions at Cerus Corporation, including vice president of chemical technology and vice president of shared sciences, where she led the discovery and product development of novel compounds for inactivation of pathogens in blood products. Dr. Wollowitz previously worked at Dow Chemical Company and has invented several novel antivirals, one of which is sold commercially in Europe, as well as novel pesticides and polymer additives. Dr. Wollowitz received her B.A. in chemistry from the State University of New York at Binghamton and her Ph.D. in organic chemistry from the University of Wisconsin at Madison. About Medivation Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation's current portfolio consists of small molecule drugs in development to treat three large, unmet medical needs -- Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. For more information, please go to http://www.medivation.com/ . DATASOURCE: Medivation, Inc. CONTACT: Patrick Machado, Chief Financial Officer of Medivation, Inc., +1-415-543-3470, ext. 201; or Jani Bergan of WeissComm Partners, +1-415-946-1064, for Medivation, Inc. Web site: http://www.medivation.com/

Copyright